Top

Published in:

01-07-2015 | Letter to the Editor

Double somatic mosaic mutations in TET2 and DNMT3A—origin of peripheral T cell lymphoma in a case

Authors: Tran B. Nguyen, Mamiko Sakata-Yanagimoto, Rie Nakamoto-Matsubara, Terukazu Enami, Yufu Ito, Toshikata Kobayashi, Naoshi Obara, Yuichi Hasegawa, Shigeru Chiba

Published in: Annals of Hematology | Issue 7/2015

Excerpt

Dear Editor, …

Available only for authorised users

Sakata-Yanagimoto M, Enami T, Yoshida K, Shiraishi Y, Ishii R, Miyake Y, Muto H, Tsuyama N, Sato-Otsubo A, Okuno Y, Sakata S, Kamada Y, Nakamoto-Matsubara R, Tran NB, Izutsu K, Sato Y, Ohta Y, Furuta J, Shimizu S, Komeno T, Sato Y, Ito T, Noguchi M, Noguchi E, Sanada M, Chiba K, Tanaka H, Suzukawa K, Nanmoku T, Hasegawa Y, Nureki O, Miyano S, Nakamura N, Takeuchi K, Ogawa S, Chiba S (2014) Somatic RHOA mutation in angioimmunoblastic T cell lymphoma. Nat Genet 46(2):171–175. doi:10.1038/ng.2872 CrossRefPubMed

Palomero T, Couronne L, Khiabanian H, Kim MY, Ambesi-Impiombato A, Perez-Garcia A, Carpenter Z, Abate F, Allegretta M, Haydu JE, Jiang X, Lossos IS, Nicolas C, Balbin M, Bastard C, Bhagat G, Piris MA, Campo E (2014) Recurrent mutations in epigenetic regulators, RHOA and FYN kinase in peripheral. T Cell Lymphom 46(2):166–170. doi:10.1038/ng.2873

Lin TL, Nagata Y, Kao HW, Sanada M, Okuno Y, Huang CF, Liang DC, Kuo MC, Lai CL, Lee EH, Shih YS, Tanaka H, Shiraishi Y, Chiba K, Lin TH, Wu JH, Miyano S, Ogawa S, Shih LY (2014) Clonal leukemic evolution in myelodysplastic syndromes with TET2 and IDH1/2 mutations. Haematologica 99(1):28–36. doi:10.3324/haematol.2013.091249 CrossRefPubMedCentralPubMed

Aslanyan MG, Kroeze LI, Langemeijer SM, Koorenhof-Scheele TN, Massop M, van Hoogen P, Stevens-Linders E, van de Locht LT, Tonnissen E, van der Heijden A, da Silva-Coelho P, Cilloni D, Saglio G, Marie JP, Tang R, Labar B, Amadori S, Muus P, Willemze R, Marijt EW, de Witte T, van der Reijden BA, Suciu S, Jansen JH (2014) Clinical and biological impact of TET2 mutations and expression in younger adult AML patients treated within the EORTC/GIMEMA AML-12 clinical trial. Ann Hematol 93(8):1401–1412. doi:10.1007/s00277-014-2055-7 PubMed

Couronne L, Bastard C, Bernard OA (2012) TET2 and DNMT3A mutations in human T-cell lymphoma. N Engl J Med 366(1):95–96. doi:10.1056/NEJMc1111708 CrossRefPubMed

Youssoufian H, Pyeritz RE (2002) Mechanisms and consequences of somatic mosaicism in humans. Nat Rev Genet 3(10):748–758. doi:10.1038/nrg906 CrossRefPubMed

Foulkes WD, Real FX (2013) Many mosaic mutations. Curr Oncol (Toronto, Ont) 20(2):85–87. doi:10.3747/co.20.1449

Frank SA (2014) Somatic mosaicism and disease. Curr Biol CB 24(12):R577–R581. doi:10.1016/j.cub.2014.05.021 CrossRef

Doisaki S, Muramatsu H, Shimada A, Takahashi Y, Mori-Ezaki M, Sato M, Kawaguchi H, Kinoshita A, Sotomatsu M, Hayashi Y, Furukawa-Hibi Y, Yamada K, Hoshino H, Kiyoi H, Yoshida N, Sakaguchi H, Narita A, Wang X, Ismael O, Xu Y, Nishio N, Tanaka M, Hama A, Koike K, Kojima S (2012) Somatic mosaicism for oncogenic NRAS mutations in juvenile myelomonocytic leukemia. Blood 120(7):1485–1488. doi:10.1182/blood-2012-02-406090 CrossRefPubMed

10.

Ismael O, Shimada A, Hama A, Elshazley M, Muramatsu H, Goto A, Sakaguchi H, Tanaka M, Takahashi Y, Yinyan X, Fukuda M, Miyajima Y, Yamashita Y, Horibe K, Hanada R, Ito M, Kojima S (2012) De novo childhood myelodysplastic/myeloproliferative disease with unique molecular characteristics. Br J Haematol 158(1):129–137. doi:10.1111/j.1365-2141.2012.09140.x CrossRefPubMed

Title: Double somatic mosaic mutations in TET2 and DNMT3A—origin of peripheral T cell lymphoma in a case
Authors: Tran B. Nguyen
Mamiko Sakata-Yanagimoto
Rie Nakamoto-Matsubara
Terukazu Enami
Yufu Ito
Toshikata Kobayashi
Naoshi Obara
Yuichi Hasegawa
Shigeru Chiba
Publication date: 01-07-2015
Publisher: Springer Berlin Heidelberg
Published in: Annals of Hematology / Issue 7/2015
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI: https://doi.org/10.1007/s00277-015-2332-0

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 7/2015

HFE hemochromatosis: influence of dietary iron intake on the iron overload of C282Y homozygous patients

Myeloproliferative neoplasm in a thalassaemic patient: response to treatment with a JAK inhibitor

De novo CSF3R mutation associated with transformation of myeloproliferative neoplasm to atypical CML

The role of paroxysmal nocturnal hemoglobinuria clones in response to immunosuppressive therapy of patients with severe aplastic anemia

CyberKnife radiosurgery leading to long-lasting complete remission in locally relapsed solitary plasmacytoma of the bone

Osteopontin: a potential biomarker of Gaucher disease

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials